A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
This single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. Adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between January 2017 and December 2024 were consecutively enrolled. Patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Waiver of informed consent for deceased or lost-to-follow-up patients (January 2017-March 2024)
- •Voluntary signed informed consent from surviving patients who could be contacted
- •Treatment at Nanfang Hospital, Southern Medical University (January 2017-December 2024)
- •Received antitumor therapy for esophageal cancer
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
排除标准
- •Concurrent other malignancies
- •Patients deemed ineligible by investigators
研究组 & 干预措施
Radiotherapy Group
Participants will receive definitive radiotherapy or radiotherapy-based combined modality therapy.
干预措施: radiotherapy (Other)
Immunotherapy Group
Participants will receive immune checkpoint inhibitors as monotherapy or in combination with other therapies.
干预措施: Immunotherapy (Drug)
Surgery Group
Participants will undergo radical esophagectomy with or without neoadjuvant/adjuvant therapy.
干预措施: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines (Procedure)
结局指标
主要结局
Overall Survival (OS)
时间窗: From the date of treatment initiation to the date of death from any cause,assessed up to 120 months.
The length of time from the start of treatment until death from any cause, evaluating the long-term survival benefit of the combined therapy.
次要结局
- Pathologic Complete Response ( pCR )(Perioperative)
- Major Pathological Response Rate (MPR)(Perioperative)
- Progression-Free Survival (PFS)(From treatment initiation to disease progression or death, assessed up to 100 months)